FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308954661> ?p ?o ?g. }

• W4308954661 endingPage "1292" @default.
• W4308954661 startingPage "1281" @default.
• W4308954661 abstract "Migraine is a worldwide epidemic neurological disorder that has a significant influence on the quality of life. Migraine attacks are considered to be related to a calcitonin gene-related peptide (CGRP) signaling molecule, and anti-CGRP medications are used to abort and prevent migraine attacks. Erenumab, a monoclonal antibody that targets the CGRP receptor, is the first migraine preventive medication approved by the US Food and Drug Administration. In the present study, we evaluate the efficacy and safety of erenumab.This study aims to systematically assess the efficacy and safety of erenumab as a migraine preventive treatment compared to a placebo.Randomized, placebo-controlled, single or double-blind trials were searched through MEDLINE, Embase, Cochrane Library, and ClinicalTrials.gov up to May 2022. The efficacy outcomes we collected include changes from baseline on monthly migraine days, monthly acute migraine-specific medication days, ≥50% responder rate, ≥75% responder rate, and 100% responder rate at week 12. Safety outcomes include treatment emergent adverse events, serious adverse events, and any adverse event that leads to discontinuation of treatment. The study was registered with PROSPERO (Registry number: CRD42022338861).In all eight included trials, we found that erenumab (28, 70, and 140 mg) is very effective and has a significantly greater reduction in baseline monthly migraine days (28 mg: mean difference [MD] = -1.1, 95% confidence interval [CI]: -2.0 to -0.2, p = 0.020; 70 mg: MD = -1.4, 95% CI: -1.8 to -1.1, p < 0.001, I2 = 26%; 140 mg: MD = -1.8, 95% CI: -2.1 to -1.4, p < 0.001, I2 = 0%) than placebo at week 12, especially with 140 mg. Otherwise, we found that there were no statistical differences in the occurrence of adverse events (7 mg: risk ratio [RR] = 0.9, 95% CI: 0.7 to 1.2, p = 0.570; 21 mg: RR = 1.0, 95% CI: 0.8 to 1.2, p = 0.730; 28 mg: RR = 0.9, 95% CI: 0.7 to 1.1, p = 0.340; 70 mg: RR = 1.0, 95% CI: 0.9 to 1.0, p = 0.230, I2 = 0%; 140 mg: RR = 1.0, 95% CI: 0.9 to 1.1, p = 0.880, I2 = 40%) between the erenumab and placebo groups.In our study, we found that erenumab, especially at the dose of 140 mg, is an effective and well-tolerated preventive treatment for migraine." @default.
• W4308954661 created "2022-11-20" @default.
• W4308954661 creator A5019560977 @default.
• W4308954661 creator A5037410853 @default.
• W4308954661 creator A5039600026 @default.
• W4308954661 creator A5045757222 @default.
• W4308954661 creator A5063131315 @default.
• W4308954661 creator A5070615073 @default.
• W4308954661 date "2022-11-01" @default.
• W4308954661 modified "2023-10-12" @default.
• W4308954661 title "Different dosage regimens of erenumab for the treatment of migraine: A systematic review and meta‐analysis of the efficacy and safety of randomized controlled trials" @default.
• W4308954661 cites W2005239637 @default.
• W4308954661 cites W2090908030 @default.
• W4308954661 cites W2098923148 @default.
• W4308954661 cites W2117200377 @default.
• W4308954661 cites W2138814983 @default.
• W4308954661 cites W2166206304 @default.
• W4308954661 cites W2268603990 @default.
• W4308954661 cites W2553868077 @default.
• W4308954661 cites W2586533881 @default.
• W4308954661 cites W2608751463 @default.
• W4308954661 cites W2613063114 @default.
• W4308954661 cites W2770965214 @default.
• W4308954661 cites W2792811290 @default.
• W4308954661 cites W2794018207 @default.
• W4308954661 cites W2801085490 @default.
• W4308954661 cites W2805937849 @default.
• W4308954661 cites W2811448052 @default.
• W4308954661 cites W2893863004 @default.
• W4308954661 cites W2898072840 @default.
• W4308954661 cites W2915483287 @default.
• W4308954661 cites W2917033428 @default.
• W4308954661 cites W2980838981 @default.
• W4308954661 cites W2982306342 @default.
• W4308954661 cites W2995764973 @default.
• W4308954661 cites W3007834801 @default.
• W4308954661 cites W3157419554 @default.
• W4308954661 cites W3176461052 @default.
• W4308954661 cites W3176839476 @default.
• W4308954661 cites W3212380527 @default.
• W4308954661 cites W4225752863 @default.
• W4308954661 cites W4294215472 @default.
• W4308954661 doi "https://doi.org/10.1111/head.14423" @default.
• W4308954661 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36373822" @default.
• W4308954661 hasPublicationYear "2022" @default.
• W4308954661 type Work @default.
• W4308954661 citedByCount "0" @default.
• W4308954661 crossrefType "journal-article" @default.
• W4308954661 hasAuthorship W4308954661A5019560977 @default.
• W4308954661 hasAuthorship W4308954661A5037410853 @default.
• W4308954661 hasAuthorship W4308954661A5039600026 @default.
• W4308954661 hasAuthorship W4308954661A5045757222 @default.
• W4308954661 hasAuthorship W4308954661A5063131315 @default.
• W4308954661 hasAuthorship W4308954661A5070615073 @default.
• W4308954661 hasConcept C126322002 @default.
• W4308954661 hasConcept C142724271 @default.
• W4308954661 hasConcept C168563851 @default.
• W4308954661 hasConcept C197934379 @default.
• W4308954661 hasConcept C204787440 @default.
• W4308954661 hasConcept C27081682 @default.
• W4308954661 hasConcept C2778541695 @default.
• W4308954661 hasConcept C2778715236 @default.
• W4308954661 hasConcept C71924100 @default.
• W4308954661 hasConcept C95190672 @default.
• W4308954661 hasConceptScore W4308954661C126322002 @default.
• W4308954661 hasConceptScore W4308954661C142724271 @default.
• W4308954661 hasConceptScore W4308954661C168563851 @default.
• W4308954661 hasConceptScore W4308954661C197934379 @default.
• W4308954661 hasConceptScore W4308954661C204787440 @default.
• W4308954661 hasConceptScore W4308954661C27081682 @default.
• W4308954661 hasConceptScore W4308954661C2778541695 @default.
• W4308954661 hasConceptScore W4308954661C2778715236 @default.
• W4308954661 hasConceptScore W4308954661C71924100 @default.
• W4308954661 hasConceptScore W4308954661C95190672 @default.
• W4308954661 hasFunder F4320321001 @default.
• W4308954661 hasFunder F4320322769 @default.
• W4308954661 hasIssue "10" @default.
• W4308954661 hasLocation W43089546611 @default.
• W4308954661 hasLocation W43089546612 @default.
• W4308954661 hasOpenAccess W4308954661 @default.
• W4308954661 hasPrimaryLocation W43089546611 @default.
• W4308954661 hasRelatedWork W2085830368 @default.
• W4308954661 hasRelatedWork W2167297145 @default.
• W4308954661 hasRelatedWork W2360693916 @default.
• W4308954661 hasRelatedWork W2415484199 @default.
• W4308954661 hasRelatedWork W2417298702 @default.
• W4308954661 hasRelatedWork W2419505618 @default.
• W4308954661 hasRelatedWork W3121096891 @default.
• W4308954661 hasRelatedWork W4320086256 @default.
• W4308954661 hasRelatedWork W4386640344 @default.
• W4308954661 hasRelatedWork W2464739384 @default.
• W4308954661 hasVolume "62" @default.
• W4308954661 isParatext "false" @default.
• W4308954661 isRetracted "false" @default.
• W4308954661 workType "article" @default.